Bausch (BHC) Down 5.4% Since Last Earnings Report: Can It Rebound?
Bausch (BHC) reported earnings 30 days ago. What's next for the stock?
Bausch Health Companies Inc. (BHC) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Bausch Health Companies Inc. (BHC) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Bausch Health Companies Inc. (BHC) Presents at Barclays 30th Annual Leveraged Finance Conference 2026 Transcript
Bausch Health Companies Inc. (BHC) Presents at Barclays 30th Annual Leveraged Finance Conference 2026 Transcript
Bausch Health: Strong Margins, Weak Volumes, Equity Story Hinges On Deleveraging
Bausch Health delivered a Q1 revenue and net profit beat, but organic growth remains weak and demand is stagnant. BHC's improved margins stem from reduced rebates and discounts, but underlying sales volumes declined, especially in key segments. The investment thesis hinges on deleveraging; if debt is reduced by 20-30%, shares could rise 15-30%, but risks remain high.
Why Bausch Health Companies Was Crawling Higher This Week
There was notable growth on both the top and bottom lines. The two metrics also topped analyst estimates.
Bausch Health Companies Inc. (BHC) Q1 2026 Earnings Call Transcript
Bausch Health Companies Inc. (BHC) Q1 2026 Earnings Call Transcript
Bausch Health (BHC) Lags Q1 Earnings Estimates
Bausch Health (BHC) came out with quarterly earnings of $0.78 per share, missing the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.59 per share a year ago.
Compared to Estimates, Bausch (BHC) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Bausch (BHC) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Is the Options Market Predicting a Spike in Bausch Health Stock?
Investors need to pay close attention to BHC stock based on the movements in the options market lately.
Bausch (BHC) Down 15.2% Since Last Earnings Report: Can It Rebound?
Bausch (BHC) reported earnings 30 days ago. What's next for the stock?
Ironwood vs. Bausch Health: Which GI Drug Stock is a Better Pick Now?
IRWD has the edge over BHC with high Linzess demand and upbeat 2026 revenue outlook offsetting pipeline and pricing risks.
BHC Stock Down on Q4 Earnings Miss, Salix Drives Revenue Growth
Bausch stock slips as Q4 EPS misses despite 9% revenue growth, strong Salix and Bausch + Lomb gains, and an upbeat 2026 sales outlook.
